Merck Serono pledges €150m to biosimilars in 2015
Merck Serono is planning to invest between €130m ($168m) and €150m ($194m) in biosimilars in 2015, depending on the outcome of ongoing Phase I studies, the company announced Thursday.
The planned investment will be made on top of the previously announced investment of €100m for 2014.
Between 2015 and 2016, Merck KGaA also plans to initiate between two and five Phase III clinical trials. The company did not respond to a request for comment by press time on which biosimilars will be included in the trials.
Existing partnerships with India’s Dr. Reddy’s and Brazil’s Bionovis will also be expanded by another, undisclosed in-licensing agreement for a late-stage biosimilar, initially for smaller emerging markets, the company said.
